# A New EBV Related Technologies of T Cells in Treating Malignant Tumors and Clinical Application

> **NCT02980315** · PHASE1,PHASE2 · UNKNOWN · sponsor: **The Second Hospital of Nanjing Medical University** · enrollment: 20 (estimated)

## Conditions studied

- Nasopharyngeal Neoplasms

## Interventions

- **OTHER:** CAR-T cells

## Key facts

- **NCT ID:** NCT02980315
- **Lead sponsor:** The Second Hospital of Nanjing Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-11
- **Primary completion:** 2017-12
- **Final completion:** 2017-12
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2016-12-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02980315

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02980315, "A New EBV Related Technologies of T Cells in Treating Malignant Tumors and Clinical Application". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02980315. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*